Skip to main content

Table 4 Association values between genotypes and metabolizer phenotypes

From: A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers

Association values between genotypes and the slow metabolizer phenotype using dominant, recessive and additive models
Gene Polymorphism Model OR (95 % CI) P-Value Pc Value
MTHFR rs1801133 Dominant (C/C vs. C/T + T/T) C/T + T/T = 0.64 (0.42–0.99)* 0.011 0.028**
    C/C = 3.11 (1.26–7.68)*   
DRD3 rs6280 Recessive (C/C + C/T vs. T/T) C/C + C/T = 0.62 (0.38–1.00) 0.015 0.034**
    T /T = 2.63 (1.21–5.70)*   
GSTM3 rs1799735 Additive (*A/*A vs. *A/*B) *A/*A = 0.88 (0.70–1.09) 0.126 0.308
    *A/*B = 3.50 (0.64–19.20)   
TNF rs1800629 Additive (G/G vs. G/A) G/G = 0.89 (0.68–1.16) 0.324 0.553
    G/A = 1.82 (0.55–6.00)   
MDR1 rs1045642 Dominant (C/C vs. C/T + T/T) C/T + T/T = 1.45 (1.18–1.77)* 0.008 0.020**
    C/C = 0.06 (0.003–1.00)   
SLCO1B1 rs4149056 Recessive (C/C + C/T vs. T/T) C/C + C/T = 1.33 (0.45–3.99) 0.610 0.884
    T/T = 0.93 (0.70–1.23)   
  1. OR odds ratio, CI confidence interval, Pc P-values adjusted by using Bonferroni’s correction for multiple comparisons, − = Not calculated, ** = P ≤ 0.05. Clusters are explained in the main text
Back to article page